Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Completes Verinata Acquisition

NEW YORK (GenomeWeb News) – Illumina said after the close of the market Thursday that it has completed its $450 million acquisition of Verinata Health.

The deal, which was inked in early January, provides Illumina with Verinata's Verifi non-invasive prenatal test for detecting trisomy 21, 18, and 13. The test analyzes cell-free fetal DNA using next-generation sequencing.

Illumina agreed to acquire Verinata for $350 million with additional potential milestone payments of up to $100 million through 2015.

"Bringing our two companies together provides a very strong collection of technologies and partners in the reproductive health market, with solutions that will lead to improved health outcomes," Illumina President and CEO Jay Flatley said in a statement.

As of the close of the deal, Verinata became a wholly owned subsidiary of Illumina. The Verifi test will continue to be offered through Verinata's CLIA- and CAP-accredited lab, and Illumina noted that the firm will continue to collect clinical data to support future regulatory submissions.

Verinata's marketing efforts also gained a boost in January through its deal with PerkinElmer, making that firm its exclusive US marketing partner for the Verifi test. PerkinElmer already has an extensive sales and marketing infrastructure aimed at the prenatal testing market.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.